Abstract Background: Heart failure (HF) is a complex clinical syndrome and a leading cause of morbidity and mortality worldwide. Its symptoms are the ultimate severe results of all heart diseases. Objectives: To assess the situation of medical care for patients with HF in a regional hospital in central Taiwan. Methods: This retrospective study was conducted from June 1, 2019, to September 30, 2021, collecting basic information of patients, hospitalization and medication after discharge, emergency room visit, readmission, and mortality. Results: This study included 101 patients with HF with reduced ejection fraction, of which 71.3% were males. Their mean age was 64.9 ± 15.4 years, and the mean body mass index was 26.4 ± 5.6 kg/m2. Moreover, 89.1% of them had chronic diseases, such as hypertension, diabetes, and heart disease; the mean left ventricular ejection fraction was 27.4% ± 7.7%. During hospitalization and at 1, 6, and 12 months after discharge, the administration rates were 61.4%, 39.6%, 26.7%, and 22.8% for angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker/angiotensin-neprilysin inhibitor; 64.4%, 41.6%, 27.7%, and 35.6% for beta-blocker; 47.5%, 26.7%, 14.9%, and 17.8% for mineralocorticoid receptor antagonist; and 4.9%, 2.0%, 1.0%, and 3.0% for sodium-glucose cotransporter-2 inhibitor, respectively. The rates of emergency room visit, readmission, and mortality due to cardiac reasons within 12 months after discharge were 18.8%, 20.8%, and 8.9%, respectively. Conclusion: Given that HF is a complex disease, the underlying causes must be treated, and the guideline-directed medical therapy must be applied to prevent the recurrence of an acute attack. Given the complexity of this high-functioning disease, it is essential to have a dedicated case manager who can ensure comprehensive integration of care.